Inhibikase Therapeutics (IKT) Cash from Financing Activities (2020 - 2026)
Inhibikase Therapeutics (IKT) reported Cash from Financing Activities of $2.9 million for Q1 2026, down 97.33% quarter-over-quarter from $108.6 million in Q4 2025.
Inhibikase Therapeutics (IKT) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 7 years of Cash from Financing Activities data on file, last reported at $2.9 million in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $2.9 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $111.4 million (up 8.0% YoY), and the FY2025 annual result was $108.5 million, up 4.82% from the prior year.
- Cash from Financing Activities fell to $2.9 million in Q1 2026 per IKT's latest filing, from $108.6 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $108.6 million in Q4 2025 and troughed at -$204769.0 in Q1 2022.
- A 5-year average of $17.2 million and a median of $181954.0 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities surged 259834.29% in 2024, then slumped 173.72% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at -$204769.0 in 2022, then jumped by 32.56% to -$138104.0 in 2023, then surged by 72280.72% to $99.7 million in 2024, then rose by 8.91% to $108.6 million in 2025, then slumped by 97.33% to $2.9 million in 2026.
- Business Quant data shows IKT's Cash from Financing Activities at $2.9 million in Q1 2026, $108.6 million in Q4 2025, and -$134130.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 85,464.43 |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - | 2.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.90 Mn |
| Mar 31, 2026 | 2.90 Mn |
| Dec 31, 2025 | 108.57 Mn |
| Dec 31, 2025 | 108.57 Mn |
| Sep 30, 2025 | -134,130.00 |
| Sep 30, 2025 | -134,130.00 |
| Jun 30, 2025 | 31,771.00 |
| Jun 30, 2025 | 31,771.00 |
| Dec 31, 2024 | 99.68 Mn |
| Dec 31, 2024 | 99.68 Mn |
| Sep 30, 2024 | 181,954.00 |
| Sep 30, 2024 | 181,954.00 |
| Jun 30, 2024 | 3.24 Mn |
| Jun 30, 2024 | 3.24 Mn |
| Mar 31, 2024 | 366,999.00 |
| Mar 31, 2024 | 366,999.00 |
| Dec 31, 2023 | -138,104.00 |
| Dec 31, 2023 | -138,104.00 |
| Sep 30, 2023 | 70.00 |
| Sep 30, 2023 | 70.00 |